Nuclear Medicine


201607 RI 集合


Chief, Takako Umeda
Chief of PET center, Yoko Sato

Nuclear medicine plays an important role in the clinic, both diagnosis and treatment. In addition to the conventional nuclear medicine, positron emission tomography is available in a PET Center, located right next to the main hospital. For the future, I anticipate that nuclear medicine makes more impact on the clinic and the research.

Research Project

Blood flow analysis for the brain

We collaborate with neurosurgeons, neurologists, and psychiatrists for the blood flow analysis in the brain using various radioisotopes, including QSPECT method with 123I-IMP, 3D-SSP analysis, eZIS analysis with 99mTc-ECD, and Dat scan with I-ioflupane.

131I treatment

131I treatment has been performed for over 3 decades in our department. Treatment effect and survival are now under studied. The relationship between the uptake in 123I scintigraphy and treatment effect by 131I is interesting topic. Recently, we have started using 89Sr and 223Ra for the treatment of bone metastases.

Positron emission tomography (PET)

FDG uptake in a tumor/tissue on PET can be a good biomarker to indicate patients’ outcome. We have been studying the usefulness/efficacy of PET in the clinics. Especially, in the patients who underwent stereotactic body radiotherapy for lung cancers.


  1. Satoh Y, Imai M, Hirata K, Asakawa Y, Ikegawa C, Onishi H:Optimal relaxation parameters of dynamic row-action maximum likelihood algorithm and post-smoothing filter for image reconstruction of dedicated breast PET. Ann Nucl Med. 35(5):608-616. 2021.   PubMed»
  2. Satoh Y, Kawamoto M, Kubota K, Murakami K, Hosono M, Senda M, Sasaki M, Momose T, Ito K, Okamura T, Oda K, Kuge Y, Sakurai M, Tateishi U, Fujibayashi Y, Magata Y, Yoshida T, Waki A, Kato K, Hashimoto T, Uchiyama M, Kinuya S, Higashi T, Magata Y, Machitori A, Maruno H, Minamimoto R, Yoshinaga K:Clinical practice guidelines for high-resolution breast PET, 2019 edition. Ann Nucl Med: , 35 (3): 404-414. 2021.  PubMed»
  3. Satoh Y, Motosugi U, Imai M, Omiya Y, Onishi H: Evaluation of image quality at the detector’s edge of dedicated breast positron emission tomography. EJNMMI Phys, 8 (1): 5. 2021.  PubMed»
  4. Satoh Y, Hirata K, Tamada D, Funayama S, Onishi H:Texture Analysis in the Diagnosis of Primary Breast Cancer: Comparison of High-Resolution Dedicated Breast Positron Emission Tomography (dbPET) and Whole-Body PET/CT. Front Med (Lausanne), 7: 603303. 2020.  PubMed»
  5. Satoh Y, Tamada D, Omiya Y, Onishi H, Motosugi U:Diagnostic Performance of the Support Vector Machine Model for Breast Cancer on Ring-Shaped Dedicated Breast Positron Emission Tomography Images. J Comput Assist Tomogr, 44(3):413-418. 2020.  PubMed»
  6. Satoh Y, Motosugi U, Imai M, Onishi H:Comparison of dedicated breast positron emission tomography and whole-body positron emission tomography/computed tomography images: a common phantom study. Ann Nucl Med, 34 (2): 119-127. 2020. PubMed»
  7. Satoh Y, Sekine T, Omiya Y, Onishi H, Motosugi U:Reduction of the fluorine-18-labeled fluorodeoxyglucose dose for clinically dedicated breast positron emission tomography. EJNMMI Phys, 6 (1): 21. 2019. PubMed»
  8. Satoh Y, Motosugi U, Omiya Y, Onishi H:Unexpected Abnormal Uptake in the Breasts at Dedicated Breast PET: Incidentally Detected Small Cancers or Nonmalignant Features? AJR Am J Roentgenol, 212 (2): 443-449. 2019.   PubMed»
  9. Satoh Y, Motosugi U, Saito A, Omiya Y, Onishi H:Pretreatment (18)F-fluorodeoxyglucose Uptake in the Lung Parenchyma Predicts Poor Survival After Stereotactic Body Radiation Therapy in Patients With Stage I Non-Small Cell Lung Cancer. Technol Cancer Res Treat, 17: 1533033818794934. 2018.  PubMed»
  10. Satoh Y, Motosugi U, Nambu A, Saito A, Onishi H:Prognostic Value of Semiautomatic CT Volumetry in Patients With Stage I Non-Small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy. J Comput Assist Tomogr, 40 (3): 343-50. 2016. PubMed »
  11. Satoh Y, Koizumi K, Nambu A, Araki T:A Case of Massive Bone Metastases From Lung Cancer Detected Only by 18F-FDG PET/CT. Clin Nucl Med, 40 (8): e411-4. 2015. PubMed»
  12. Satoh Y, Onishi H, Nambu A, Araki T:Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value. Radiology, 270 (1): 275-81. 2014. PubMed »
  13. Satoh Y, Nambu A, Ichikawa T, Onishi H:Whole-body total lesion glycolysis measured on fluorodeoxyglucose positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer. BMC Cancer, 14: 525. 2014. PubMed »
  14. Satoh Y, Nambu A, Onishi H, Sawada E, Tominaga L, Kuriyama K, Komiyama T, Marino K, Aoki S, Araya M, Saito R, Maehata Y, Oguri M, Araki T:Value of dual time point F-18 FDG-PET/CT imaging for the evaluation of prognosis and risk factors for recurrence in patients with stage I non-small cell lung cancer treated with stereotactic body radiation therapy. Eur J Radiol, 81 (11): 3530-4. 2012. PubMed »
  15. Satoh Y, Ichikawa T, Motosugi U, Kimura K, Sou H, Sano K, Araki T:Diagnosis of peritoneal dissemination: comparison of 18F-FDG PET/CT, diffusion-weighted MRI, and contrast-enhanced MDCT. AJR Am J Roentgenol, 196 (2): 447-53. 2011. PubMed »